+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Endocrine And Metabolic Disorders Drugs Market Research Reports

Batten Disease Epidemiology Forecast 2025-2034 - Product Thumbnail Image

Batten Disease Epidemiology Forecast 2025-2034

  • Report
  • May 2025
  • 150 Pages
  • Global
From
Lipodystrophy Syndrome Epidemiology Forecast 2025-2034 - Product Thumbnail Image

Lipodystrophy Syndrome Epidemiology Forecast 2025-2034

  • Report
  • May 2025
  • 150 Pages
  • Global
From
Somatotropin Deficiency Drug Pipeline Analysis Report 2025 - Product Thumbnail Image

Somatotropin Deficiency Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • May 2025
  • 100 Pages
  • Global
From
GLP-1 Agonists Drug Pipeline Analysis Report 2025 - Product Thumbnail Image

GLP-1 Agonists Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • May 2025
  • 100 Pages
  • Global
From
From
Palmar Hyperhidrosis Epidemiology Forecast 2025-2034 - Product Thumbnail Image

Palmar Hyperhidrosis Epidemiology Forecast 2025-2034

  • Report
  • May 2025
  • 150 Pages
  • Global
From
Diabetic Retinopathy Epidemiology Forecast 2025-2034 - Product Thumbnail Image

Diabetic Retinopathy Epidemiology Forecast 2025-2034

  • Report
  • May 2025
  • 150 Pages
  • Global
From
Prediabetes Epidemiology Forecast 2025-2034 - Product Thumbnail Image

Prediabetes Epidemiology Forecast 2025-2034

  • Report
  • May 2025
  • 150 Pages
  • Global
From
From
Diabetic Retinopathy Treatment Market Report and Forecast 2024-2032 - Product Thumbnail Image

Diabetic Retinopathy Treatment Market Report and Forecast 2024-2032

  • Report
  • September 2024
  • 250 Pages
  • Global
From
Hunter Syndrome Treatment Market Report and Forecast 2024-2032 - Product Thumbnail Image

Hunter Syndrome Treatment Market Report and Forecast 2024-2032

  • Report
  • September 2024
  • 250 Pages
  • Global
From
From
From
Hunter Syndrome - Pipeline Insight, 2025 - Product Thumbnail Image

Hunter Syndrome - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Dementia With Diabetes - Pipeline Insight, 2025 - Product Thumbnail Image

Dementia With Diabetes - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 40 Pages
  • Global
From
Chronic Pancreatitis - Pipeline Insight, 2025 - Product Thumbnail Image

Chronic Pancreatitis - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 40 Pages
  • Global
From
Hereditary Transthyretin Amyloidosis (hATTR) - Pipeline Insight, 2025 - Product Thumbnail Image

Hereditary Transthyretin Amyloidosis (hATTR) - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 40 Pages
  • Global
From
Familial Chylomicronemia Syndrome - Pipeline Insight, 2025 - Product Thumbnail Image

Familial Chylomicronemia Syndrome - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Fibroblast Growth Factor 2 (FGFR2) - Pipeline Insight, 2025 - Product Thumbnail Image

Fibroblast Growth Factor 2 (FGFR2) - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 90 Pages
  • Global
From
Niemann Pick C Disease- Pipeline Insight, 2025 - Product Thumbnail Image

Niemann Pick C Disease- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Loading Indicator

The Endocrine and Metabolic Disorders Drugs market is a segment of the pharmaceutical industry that focuses on the development and production of drugs used to treat endocrine and metabolic disorders. Endocrine disorders are conditions that affect the body's hormones, while metabolic disorders are conditions that affect the body's ability to process and use energy. Endocrine and metabolic disorders can include diabetes, thyroid disorders, obesity, and adrenal disorders. Endocrine and Metabolic Disorders Drugs are typically developed by pharmaceutical companies and are prescribed by physicians. These drugs can be used to treat a variety of endocrine and metabolic disorders, including diabetes, thyroid disorders, obesity, and adrenal disorders. Common drugs used to treat these conditions include insulin, metformin, and glucagon-like peptide-1 (GLP-1) agonists. Some of the major companies in the Endocrine and Metabolic Disorders Drugs market include Novo Nordisk, Sanofi, Eli Lilly, Merck, and AstraZeneca. These companies are involved in the development, production, and marketing of drugs used to treat endocrine and metabolic disorders. Show Less Read more